Conatus Pharmaceutic (CNAT) Stock Price & Overview

NASDAQ:CNAT

Current stock price

0.556
+0 (+0.18%)
At close:
0.54
-0.02 (-2.88%)
After Hours:

The current stock price of CNAT is 0.556 null. Today CNAT is up by 0.18%. In the past month the price increased by 61.16%. In the past year, price decreased by -28.02%.

CNAT Key Statistics

52-Week Range0.2303 - 1.07
Current CNAT stock price positioned within its 52-week range.
1-Month Range0.33 - 0.75
Current CNAT stock price positioned within its 1-month range.
Market Cap
18.443M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.34
Dividend Yield
N/A

CNAT Stock Performance

Today
+0.18%
1 Week
-13.80%
1 Month
+61.16%
3 Months
+40.72%
Longer-term
6 Months +50.43%
1 Year -28.02%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CNAT Stock Chart

Conatus Pharmaceutic / CNAT Daily stock chart

CNAT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CNAT. When comparing the yearly performance of all stocks, CNAT is one of the better performing stocks in the market, outperforming 72.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
CNAT Full Technical Analysis Report

CNAT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CNAT. While CNAT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CNAT Full Fundamental Analysis Report

CNAT Earnings

Next Earnings DateN/A
Last Earnings DateN/A
CNAT Earnings History

CNAT Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next Y-2.94%
Revenue Next YearN/A
CNAT Forecast & Estimates

CNAT Financial Highlights

Over the last trailing twelve months CNAT reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 42.37% compared to the year before.


Income Statements
Revenue(TTM)14.69M
Net Income(TTM)-10.12M
Industry RankSector Rank
PM (TTM) -68.87%
ROA -53.86%
ROE N/A
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%38.46%
Sales Q2Q%-100%
EPS 1Y (TTM)42.37%
Revenue 1Y (TTM)-52.41%
CNAT financials

CNAT Ownership

Ownership
Inst Owners15.2%
Shares33.17M
Float27.06M
Ins Owners5.21%
Short Float %N/A
Short RatioN/A
CNAT Ownership

About CNAT

Company Profile

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.

Company Info

Conatus Pharmaceutic

16745 W. Bernardo Dr. Suite 250

San Diego CA 92127

CEO: Steven J. Mento

Phone: 858-376-2600

Conatus Pharmaceutic / CNAT FAQ

Can you describe the business of Conatus Pharmaceutic?

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.


What is the stock price of Conatus Pharmaceutic today?

The current stock price of CNAT is 0.556 null. The price increased by 0.18% in the last trading session.


Does Conatus Pharmaceutic pay dividends?

CNAT does not pay a dividend.


What is the ChartMill technical and fundamental rating of CNAT stock?

CNAT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the ownership details for CNAT stock?

You can find the ownership structure of Conatus Pharmaceutic (CNAT) on the Ownership tab.